Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Comparative Proteomic Analysis of Tumor Mesenchymal-Like Stem Cells Derived from High Grade versus Low Grade Gliomas.

Taghipour M, Omidvar A, Razmkhah M, Ghaderi A, Mojtahedi Z.

Cell J. 2017 Jul-Sep;19(2):250-258. doi: 10.22074/cellj.2016.4179. Epub 2017 Feb 22.

2.

Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery.

Cimino PJ, Zager M, McFerrin L, Wirsching HG, Bolouri H, Hentschel B, von Deimling A, Jones D, Reifenberger G, Weller M, Holland EC.

Acta Neuropathol Commun. 2017 May 22;5(1):39. doi: 10.1186/s40478-017-0443-7.

3.

Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying).

Ostrom QT, Gittleman H, Kruchko C, Louis DN, Brat DJ, Gilbert MR, Petkov VI, Barnholtz-Sloan JS.

J Neurooncol. 2016 Oct;130(1):31-42. Epub 2016 Jul 14.

PMID:
27418206
4.

MethylMeter(®): bisulfite-free quantitative and sensitive DNA methylation profiling and mutation detection in FFPE samples.

McCarthy D, Pulverer W, Weinhaeusel A, Diago OR, Hogan DJ, Ostertag D, Hanna MM.

Epigenomics. 2016 Jun;8(6):747-65. doi: 10.2217/epi-2016-0004. Epub 2016 Jun 23.

5.

World Health Organization grade II-III astrocytomas consist of genetically distinct tumor lineages.

Hattori N, Hirose Y, Sasaki H, Nakae S, Hayashi S, Ohba S, Adachi K, Hayashi T, Nishiyama Y, Hasegawa M, Abe M.

Cancer Sci. 2016 Aug;107(8):1159-64. doi: 10.1111/cas.12969. Epub 2016 Jun 22.

6.

Differences in the Pathological Diagnosis and Repeat Craniotomy Rates in Cerebral Tumors Undergoing Biopsy or Resection in an Urban Versus Regional Center.

Vonhoff CR, Lochhead A, Koustais S, Watson N, Andrici J, Brewer J, Gill AJ.

Medicine (Baltimore). 2015 Nov;94(47):e2131. doi: 10.1097/MD.0000000000002131.

7.

Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539.

Rogers CL, Perry A, Pugh S, Vogelbaum MA, Brachman D, McMillan W, Jenrette J, Barani I, Shrieve D, Sloan A, Bovi J, Kwok Y, Burri SH, Chao ST, Spalding AC, Anscher MS, Bloom B, Mehta M.

Neuro Oncol. 2016 Apr;18(4):565-74. doi: 10.1093/neuonc/nov247. Epub 2015 Oct 22.

8.

Combination genetic signature stratifies lower-grade gliomas better than histological grade.

Chan AK, Yao Y, Zhang Z, Shi Z, Chen L, Chung NY, Liu JS, Li KK, Chan DT, Poon WS, Wang Y, Zhou L, Ng HK.

Oncotarget. 2015 Aug 28;6(25):20885-901.

9.

Molecular-genetic and clinical characteristics of gliomas with astrocytic appearance and total 1p19q loss in a single institutional consecutive cohort.

Hayashi S, Sasaki H, Kimura T, Abe T, Nakamura T, Kitamura Y, Miwa T, Kameyama K, Hirose Y, Yoshida K.

Oncotarget. 2015 Jun 30;6(18):15871-81.

10.

Improved cytodiagnostics and quality of patient care through double reading of selected cases by an expert cytopathologist.

Kuijpers CC, Visser M, Sie-Go DM, de Leeuw H, de Rooij MJ, van Diest PJ, Jiwa M.

Virchows Arch. 2015 Jun;466(6):617-24. doi: 10.1007/s00428-015-1738-3. Epub 2015 Mar 17.

11.

The diagnostic properties of frozen sections in suspected intracranial tumors: A study of 578 consecutive cases.

Tofte K, Berger C, Torp SH, Solheim O.

Surg Neurol Int. 2014 Dec 3;5:170. doi: 10.4103/2152-7806.146153. eCollection 2014.

12.

Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas.

Cryan JB, Haidar S, Ramkissoon LA, Bi WL, Knoff DS, Schultz N, Abedalthagafi M, Brown L, Wen PY, Reardon DA, Dunn IF, Folkerth RD, Santagata S, Lindeman NI, Ligon AH, Beroukhim R, Hornick JL, Alexander BM, Ligon KL, Ramkissoon SH.

Oncotarget. 2014 Sep 30;5(18):8083-92.

13.

A unique four-hub protein cluster associates to glioblastoma progression.

Simeone P, Trerotola M, Urbanella A, Lattanzio R, Ciavardelli D, Di Giuseppe F, Eleuterio E, Sulpizio M, Eusebi V, Pession A, Piantelli M, Alberti S.

PLoS One. 2014 Jul 22;9(7):e103030. doi: 10.1371/journal.pone.0103030. eCollection 2014.

14.

1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas.

Jiang H, Ren X, Cui X, Wang J, Jia W, Zhou Z, Lin S.

Neuro Oncol. 2013 Jun;15(6):775-82. doi: 10.1093/neuonc/not027. Epub 2013 Mar 13.

15.

Risk of subsequent cancer following a primary CNS tumor.

Strodtbeck K, Sloan A, Rogers L, Fisher PG, Stearns D, Campbell L, Barnholtz-Sloan J.

J Neurooncol. 2013 Apr;112(2):285-95. doi: 10.1007/s11060-013-1063-0. Epub 2013 Feb 8.

16.

Demographic variation in incidence of adult glioma by subtype, United States, 1992-2007.

Dubrow R, Darefsky AS.

BMC Cancer. 2011 Jul 29;11:325. doi: 10.1186/1471-2407-11-325.

17.

Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective.

van den Bent MJ.

Acta Neuropathol. 2010 Sep;120(3):297-304. doi: 10.1007/s00401-010-0725-7. Epub 2010 Jul 20. Review.

18.

Daily intake of antioxidants in relation to survival among adult patients diagnosed with malignant glioma.

DeLorenze GN, McCoy L, Tsai AL, Quesenberry CP Jr, Rice T, Il'yasova D, Wrensch M.

BMC Cancer. 2010 May 19;10:215. doi: 10.1186/1471-2407-10-215.

19.

Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium.

Bondy ML, Scheurer ME, Malmer B, Barnholtz-Sloan JS, Davis FG, Il'yasova D, Kruchko C, McCarthy BJ, Rajaraman P, Schwartzbaum JA, Sadetzki S, Schlehofer B, Tihan T, Wiemels JL, Wrensch M, Buffler PA; Brain Tumor Epidemiology Consortium.

Cancer. 2008 Oct 1;113(7 Suppl):1953-68. doi: 10.1002/cncr.23741. Review.

20.

Genomic analysis of pilocytic astrocytomas at 0.97 Mb resolution shows an increasing tendency toward chromosomal copy number change with age.

Jones DT, Ichimura K, Liu L, Pearson DM, Plant K, Collins VP.

J Neuropathol Exp Neurol. 2006 Nov;65(11):1049-58.

Supplemental Content

Support Center